|  |  |  |  |
| --- | --- | --- | --- |
| Study ID |       | PI |       |

Research activities that (1) present no more than minimal risk to human subjects, and (2) involve only procedures listed in one or more of the following categories, may be reviewed by the IRB through the expedited review procedure authorized by 45 CFR 46.110 and 21 CFR 56.110.

|  |
| --- |
| **Common Rule Requirements** |
| 1. **Is this project conducted, supported, or required to comply with the Revised Common Rule (2018 Requirements)?**

[ ]  No 🡪 Continue[ ]  Yes 🡪 *Do NOT use this form; use the HRP-313 - Worksheet – Expedited Review Revised Common Rule.* |
| **Minimal Risk** |
| **(1)** | **By checking the box, I confirm that the project involves minimal risk.**  |
| [ ]  | The project involves minimal risk. “Minimal Risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.” 45 CFR 46.102(i), 21 CFR 50.3(k). *a, b*  |
|  | Comments:       |
| *a For research involving prisoners as subjects, see 45 CFR 46.303(d) for the definition of minimal risk.**b For research that is funded by the Department of Defense, see DoD Instruction 3216.02, Enclosure 3, Item 6(a) for interpretation of minimal risk definition.* |
| ***If the research is more than minimal risk, the project is not eligible for expedited review.*** |
| **Expedited Review Category(ies)** |

|  |
| --- |
| **(2) Select the appropriate expedited review category(ies) below to confirm that the research involves only procedures listed in one or more of the expedited review categories and explain why it meets that category(ies).** |
| [ ]  1(a) | (i) Clinical studies of drugs and medical devices only when: (ii) Research on drugs for which an investigational new drug application (21 CFR Part 312) is not required. (Note: Research on marketed drugs that significantly increases the risks or decreases the acceptability of the risks associated with the use of the product is not eligible for expedited review.) |
| Explanation |       |
| [ ] 1(b)(i) | (i) Clinical studies of drugs and medical devices only when: (ii) Research on medical devices for which (i) an investigational device exemption application (21 CFR Part 812) is not required. |
| Explanation |       |
| [ ] 1(b)(ii) | (i) Clinical studies of drugs and medical devices only when: (ii) Research on medical devices for which the medical device is cleared/approved for marketing and the medical device is being used in accordance with its cleared/approved labeling. |
| Explanation |       |
| [ ]  2(a) | (i) Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (ii) from healthy, nonpregnant adults (iii) who weigh at least 110 pounds. For these subjects, (iv) the amounts drawn may not exceed 550 ml in an 8 week period and (v) collection may not occur more frequently than 2 times per week. |
| Explanation |       |
| [ ]  2(b) | (i) Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows: (ii) from other adults and children2, (iii) considering the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected. For these subjects, (iv) the amount drawn may not exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and (v) collection may not occur more frequently than 2 times per week. |
| Explanation |       |
| [ ]  3 | (i) Prospective collection of (ii) biological specimens (iii) for research purposes (iv) by noninvasive means. Examples: (a) hair and nail clippings in a nondisfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gumbase or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) amniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization. |
| Explanation |       |
| [ ]  4 | (i) Collection of data through noninvasive procedures (not involving general anesthesia or sedation) (ii) routinely employed in clinical practice, (iii) *excluding procedures involving x-rays or microwaves*. (iv) Where medical devices are employed, they must be cleared/approved for marketing. (Studies intended to evaluate the safety and effectiveness of the medical device are not generally eligible for expedited review, including studies of cleared medical devices for new indications.) Examples: (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject=s privacy; (b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, doppler blood flow, and echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual. |
| Explanation |       |
| [ ]  5 | (i) Research involving materials (data, documents, records, or specimens) that (ii) have been collected, or will be collected (iii) solely for nonresearch purposes (such as medical treatment or diagnosis). (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(4). This listing refers only to research that is not exempt.) |
| Explanation |       |
| [ ]  6 | (i) Collection of data from voice, video, digital, or image recordings (ii) made for research purposes. |
| Explanation |       |
| [ ]  7 | (i) Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior) or (ii) research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies. (NOTE: Some research in this category may be exempt from the HHS regulations for the protection of human subjects. 45 CFR 46.101(b)(2) and (b)(3). This listing refers only to research that is not exempt.) |
| Explanation |       |
| [ ] 8(a) | (i) Continuing review of research previously approved by the convened IRB as follows: (ii) where the research is permanently closed to the enrollment of new subjects; (iii) all subjects have completed all research-related interventions; and (iv) the research remains active only for long-term follow-up of subjects. |
| Explanation |       |
| [ ]  8(b) | (i) Continuing review of research previously approved by the convened IRB as follows: (ii) where no subjects have been enrolled and (iii) no additional risks have been identified |
| Explanation |       |
| [ ]  8(c) | (i) Continuing review of research previously approved by the convened IRB as follows: (ii) where the remaining research activities are limited to data analysis. |
| Explanation |       |
| [ ]  9 | (i) Continuing review of research, (ii) not conducted under an investigational new drug application or investigational device exemption (iii) where categories two (2) through eight (8) do not apply but the IRB has (iv) determined and documented at a convened meeting that (v) the research involves no greater than minimal risk and (vi) no additional risks have been identified. |
| Explanation |       |
| Applicability1. Research activities that (1) present no more than minimal risk to human subjects, and (2) involve only procedures listed in one or more of the following categories, may be reviewed by the IRB through the expedited review procedure authorized by 45 CFR 46.110 and 21 CFR 56.110. The activities listed should not be deemed to be of minimal risk simply because they are included on this list. Inclusion on this list merely means that the activity is eligible for review through the expedited review procedure when the specific circumstances of the proposed research involve no more than minimal risk to human subjects.
2. The categories in this list apply regardless of the age of subjects, except as noted.
3. The expedited review procedure may not be used where identification of the subjects and/or their responses would reasonably place them at risk of criminal or civil liability or be damaging to the subjects= financial standing, employability, insurability, reputation, or be stigmatizing, unless reasonable and appropriate protections will be implemented so that risks related to invasion of privacy and breach of confidentiality are no greater than minimal.
4. The expedited review procedure may not be used for classified research involving human subjects.
5. IRBs are reminded that the standard requirements for informed consent (or its waiver, alteration, or exception) apply regardless of the type of review--expedited or convened--utilized by the IRB.
6. Categories one (1) through seven (7) pertain to both initial and continuing IRB review.
 |

[ ]  Research is Eligible for expedited review

[ ]  Proceed with expedited review

[ ]  Although research is eligible for expedited review, proceed with review by the convened IRB

[ ]  Research is NOT Eligible for Expedited Review; proceed with review by the convened IRB

Comments:

|  |
| --- |
| IRB determination made by: |
| [ ]  Expedited reviewer | Name: |       | Date: |       |  |
|  |
| [ ]  Full board | Name of individual completing this form: |       | Meeting date |       |
|  |